Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endosonography | 19 | 2018 | 55 | 3.110 |
Why?
|
| Adenocarcinoma | 10 | 2010 | 298 | 1.100 |
Why?
|
| Pancreatic Neoplasms | 7 | 2006 | 131 | 0.950 |
Why?
|
| Biliary Tract | 2 | 2012 | 7 | 0.680 |
Why?
|
| Biliary Tract Diseases | 2 | 2012 | 12 | 0.680 |
Why?
|
| Cholestasis | 2 | 2012 | 18 | 0.650 |
Why?
|
| Pancreatic Cyst | 3 | 2018 | 4 | 0.600 |
Why?
|
| Biopsy, Fine-Needle | 6 | 2009 | 62 | 0.560 |
Why?
|
| Incidental Findings | 1 | 2017 | 25 | 0.510 |
Why?
|
| Digestive System Diseases | 1 | 2016 | 5 | 0.490 |
Why?
|
| Lymphatic Diseases | 2 | 2012 | 11 | 0.430 |
Why?
|
| Lymph Nodes | 2 | 2012 | 113 | 0.410 |
Why?
|
| Kidney Transplantation | 1 | 2017 | 490 | 0.380 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2018 | 23 | 0.380 |
Why?
|
| Pancreatitis, Acute Necrotizing | 2 | 2018 | 5 | 0.360 |
Why?
|
| Humans | 39 | 2018 | 32262 | 0.340 |
Why?
|
| Colonoscopy | 2 | 2018 | 45 | 0.320 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2010 | 4 | 0.320 |
Why?
|
| Retrospective Studies | 11 | 2018 | 3609 | 0.310 |
Why?
|
| Gastrostomy | 1 | 2010 | 17 | 0.310 |
Why?
|
| Sensitivity and Specificity | 6 | 2012 | 556 | 0.300 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2008 | 13 | 0.290 |
Why?
|
| Liver Diseases | 1 | 2009 | 72 | 0.280 |
Why?
|
| Female | 25 | 2018 | 19935 | 0.270 |
Why?
|
| Male | 23 | 2018 | 19429 | 0.260 |
Why?
|
| Pancreatitis, Chronic | 3 | 2016 | 8 | 0.260 |
Why?
|
| Appendiceal Neoplasms | 1 | 2008 | 99 | 0.260 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 4 | 2016 | 29 | 0.260 |
Why?
|
| Middle Aged | 20 | 2018 | 11837 | 0.250 |
Why?
|
| Adult | 16 | 2018 | 9252 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2010 | 442 | 0.250 |
Why?
|
| Esophageal Neoplasms | 4 | 2010 | 39 | 0.250 |
Why?
|
| Liver | 2 | 2009 | 492 | 0.250 |
Why?
|
| Aged | 16 | 2018 | 10249 | 0.240 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 2238 | 0.240 |
Why?
|
| Telomerase | 1 | 2006 | 20 | 0.240 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 52 | 0.240 |
Why?
|
| Peritoneal Neoplasms | 1 | 2008 | 256 | 0.230 |
Why?
|
| DNA | 1 | 2006 | 223 | 0.220 |
Why?
|
| Cholecystectomy, Laparoscopic | 2 | 2016 | 21 | 0.200 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2010 | 52 | 0.190 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 120 | 0.190 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 500 | 0.190 |
Why?
|
| Hepatitis C | 1 | 2003 | 47 | 0.190 |
Why?
|
| Veterans | 1 | 2003 | 64 | 0.190 |
Why?
|
| Aged, 80 and over | 9 | 2016 | 3893 | 0.180 |
Why?
|
| Antineoplastic Agents | 1 | 2003 | 595 | 0.140 |
Why?
|
| Necrosis | 1 | 2018 | 53 | 0.140 |
Why?
|
| Pancreatectomy | 1 | 2018 | 25 | 0.140 |
Why?
|
| Journal Impact Factor | 1 | 2018 | 11 | 0.140 |
Why?
|
| Pancreatitis | 3 | 2011 | 20 | 0.140 |
Why?
|
| Deoxycytidine | 3 | 2010 | 57 | 0.140 |
Why?
|
| Curriculum | 2 | 2012 | 203 | 0.130 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 880 | 0.130 |
Why?
|
| Radiopharmaceuticals | 3 | 2010 | 95 | 0.130 |
Why?
|
| Pancreas | 4 | 2010 | 107 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 161 | 0.130 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 90 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2017 | 125 | 0.120 |
Why?
|
| Choledocholithiasis | 1 | 2016 | 4 | 0.120 |
Why?
|
| Intraoperative Care | 1 | 2016 | 52 | 0.120 |
Why?
|
| Self Concept | 1 | 2016 | 45 | 0.120 |
Why?
|
| Needles | 1 | 2016 | 28 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 246 | 0.110 |
Why?
|
| Colonic Polyps | 2 | 2018 | 17 | 0.110 |
Why?
|
| Esophagectomy | 2 | 2010 | 15 | 0.100 |
Why?
|
| Prognosis | 1 | 2017 | 1529 | 0.100 |
Why?
|
| Child, Preschool | 1 | 2016 | 1233 | 0.090 |
Why?
|
| Abdomen | 1 | 2012 | 44 | 0.090 |
Why?
|
| Child | 2 | 2016 | 2430 | 0.090 |
Why?
|
| Ultrasonography, Interventional | 1 | 2012 | 55 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 83 | 0.090 |
Why?
|
| Positron-Emission Tomography | 2 | 2010 | 170 | 0.090 |
Why?
|
| Cholelithiasis | 1 | 2011 | 10 | 0.080 |
Why?
|
| Combined Modality Therapy | 6 | 2011 | 551 | 0.080 |
Why?
|
| Adolescent | 2 | 2016 | 3509 | 0.080 |
Why?
|
| Comorbidity | 2 | 2011 | 563 | 0.080 |
Why?
|
| Quality of Life | 1 | 2016 | 968 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2016 | 2315 | 0.080 |
Why?
|
| Young Adult | 1 | 2017 | 2643 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 544 | 0.080 |
Why?
|
| Catheterization | 1 | 2010 | 55 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2010 | 650 | 0.070 |
Why?
|
| Survival Rate | 3 | 2006 | 892 | 0.070 |
Why?
|
| Bile Duct Neoplasms | 1 | 2009 | 33 | 0.070 |
Why?
|
| Gallbladder Neoplasms | 1 | 2009 | 35 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 276 | 0.070 |
Why?
|
| Radiography | 1 | 2009 | 358 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 212 | 0.070 |
Why?
|
| Forecasting | 1 | 2008 | 144 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 164 | 0.070 |
Why?
|
| Clinical Competence | 2 | 2007 | 329 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2009 | 200 | 0.060 |
Why?
|
| Genes, ras | 1 | 2006 | 26 | 0.060 |
Why?
|
| False Positive Reactions | 1 | 2006 | 27 | 0.060 |
Why?
|
| Disease Progression | 2 | 2006 | 591 | 0.060 |
Why?
|
| Celiac Plexus | 1 | 2006 | 3 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 46 | 0.060 |
Why?
|
| Bile Duct Diseases | 1 | 2006 | 10 | 0.060 |
Why?
|
| Nerve Block | 1 | 2006 | 57 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2009 | 1423 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2006 | 62 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1478 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 186 | 0.060 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 30 | 0.060 |
Why?
|
| Vomiting | 1 | 2005 | 20 | 0.060 |
Why?
|
| Camptothecin | 1 | 2005 | 45 | 0.060 |
Why?
|
| Education, Medical | 1 | 2006 | 69 | 0.060 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2005 | 2 | 0.060 |
Why?
|
| Nausea | 1 | 2005 | 50 | 0.060 |
Why?
|
| Colchicine | 1 | 2005 | 8 | 0.060 |
Why?
|
| Diarrhea | 1 | 2005 | 56 | 0.060 |
Why?
|
| Abdominal Pain | 1 | 2005 | 44 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 50 | 0.060 |
Why?
|
| Fatigue | 1 | 2005 | 80 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 854 | 0.050 |
Why?
|
| Rectal Neoplasms | 1 | 2005 | 19 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 322 | 0.050 |
Why?
|
| Mutation | 1 | 2006 | 497 | 0.050 |
Why?
|
| Pain | 1 | 2006 | 302 | 0.050 |
Why?
|
| Cholangiography | 2 | 2016 | 12 | 0.050 |
Why?
|
| Genes, erbB-1 | 1 | 2003 | 14 | 0.050 |
Why?
|
| Diphtheria Toxin | 1 | 2003 | 28 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2018 | 3408 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2007 | 317 | 0.050 |
Why?
|
| Radiotherapy Dosage | 3 | 2010 | 106 | 0.050 |
Why?
|
| Injections | 1 | 2003 | 72 | 0.050 |
Why?
|
| Georgia | 1 | 2003 | 15 | 0.050 |
Why?
|
| Angioedema | 1 | 2003 | 3 | 0.050 |
Why?
|
| Viscera | 1 | 2003 | 13 | 0.050 |
Why?
|
| Enalapril | 1 | 2003 | 8 | 0.050 |
Why?
|
| Florida | 1 | 2003 | 41 | 0.050 |
Why?
|
| Prisoners | 1 | 2003 | 12 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2010 | 458 | 0.050 |
Why?
|
| Hospitals, Veterans | 1 | 2003 | 44 | 0.050 |
Why?
|
| Cell Survival | 1 | 2003 | 286 | 0.050 |
Why?
|
| Stomach Diseases | 1 | 2002 | 7 | 0.050 |
Why?
|
| Choristoma | 1 | 2002 | 14 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2010 | 185 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 133 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 93 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2002 | 70 | 0.050 |
Why?
|
| Liver Transplantation | 1 | 2003 | 185 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 388 | 0.040 |
Why?
|
| Substance-Related Disorders | 1 | 2003 | 140 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2003 | 727 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2016 | 566 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 756 | 0.040 |
Why?
|
| Disinfection | 1 | 2018 | 6 | 0.030 |
Why?
|
| Barrett Esophagus | 1 | 2018 | 4 | 0.030 |
Why?
|
| Equipment Contamination | 1 | 2018 | 13 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 74 | 0.030 |
Why?
|
| False Negative Reactions | 2 | 2011 | 22 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2009 | 1839 | 0.030 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2018 | 28 | 0.030 |
Why?
|
| Adenoma | 1 | 2018 | 35 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2011 | 904 | 0.030 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2018 | 65 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 197 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 321 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 129 | 0.030 |
Why?
|
| Stents | 1 | 2018 | 159 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 76 | 0.030 |
Why?
|
| United States | 2 | 2018 | 4068 | 0.030 |
Why?
|
| Videotape Recording | 1 | 2016 | 13 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 219 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 70 | 0.030 |
Why?
|
| Psychometrics | 1 | 2016 | 137 | 0.030 |
Why?
|
| Risk Factors | 1 | 2003 | 3933 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2006 | 156 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2005 | 476 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2005 | 413 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 49 | 0.020 |
Why?
|
| Animals | 1 | 2003 | 8196 | 0.020 |
Why?
|
| Cholagogues and Choleretics | 1 | 2011 | 3 | 0.020 |
Why?
|
| Technetium Tc 99m Lidofenin | 1 | 2011 | 3 | 0.020 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2011 | 4 | 0.020 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2011 | 8 | 0.020 |
Why?
|
| Ceftriaxone | 1 | 2011 | 15 | 0.020 |
Why?
|
| Obesity | 1 | 2018 | 1111 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 32 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2011 | 40 | 0.020 |
Why?
|
| Age of Onset | 1 | 2011 | 90 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2010 | 3 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 92 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2011 | 93 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2010 | 57 | 0.020 |
Why?
|
| Medical Records | 1 | 2010 | 75 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 79 | 0.020 |
Why?
|
| Observer Variation | 1 | 2010 | 96 | 0.020 |
Why?
|
| Contrast Media | 1 | 2010 | 136 | 0.020 |
Why?
|
| Video Recording | 1 | 2010 | 61 | 0.020 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2009 | 4 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 28 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 141 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 155 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2009 | 113 | 0.020 |
Why?
|
| Conscious Sedation | 1 | 2007 | 24 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2007 | 40 | 0.020 |
Why?
|
| Anesthesia | 1 | 2007 | 63 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 99 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 13 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2011 | 818 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2005 | 27 | 0.010 |
Why?
|
| Recurrence | 1 | 2006 | 286 | 0.010 |
Why?
|
| Morbidity | 1 | 2005 | 98 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2005 | 164 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 716 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 287 | 0.010 |
Why?
|
| Mediastinum | 1 | 2004 | 14 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2004 | 52 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2006 | 373 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2006 | 393 | 0.010 |
Why?
|
| Ethnic Groups | 1 | 2006 | 450 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 395 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2002 | 184 | 0.010 |
Why?
|
| Algorithms | 1 | 2002 | 536 | 0.010 |
Why?
|
| Hypertension | 1 | 2003 | 980 | 0.010 |
Why?
|